Form 8-K AbbVie Inc. For: Apr 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up 1% as Saudi Arabian refinery attack reignites supply concerns
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
- Seagate Technology (STX) Tops Q1 EPS by 29c, Offers Guidance
AbbVie (ABBV) issues updated guidance
April 3, 2025 4:15 PM EDTAbbVie (NYSE: ABBV):
Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final... More



